Clozapine serum concentrations are lower in smoking than in non-smoking schizophrenic patients

Pharmacology and Toxicology

Volumn 85, Issue 5, 1999, Pages 244-246

  Seppälä, Niko H ^a,b,d   Leinonen, Esa V J ^a,b   Lehtonen, Maija Liisa ^a   Kivistö, Kari T ^c  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d Tampere Community Mental Health Care   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; CYTOCHROME P450; DRUG METABOLITE; NORCLOZAPINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG METABOLISM; ENZYME INDUCTION; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SMOKING;

EID: 0032711713     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0773.1999.tb02016.x     Document Type: Article

References (22)

1. Bertilsson, L., J. A. Carrillo, M.-L. Dahl, A. Llerena, C. Alm, U. Bondesson, L. Lindström, I. Rodriguez de la Rubia, S. Ramos & J. Benitez: Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Brit. J. Clin. Pharmacol. 1994, 38, 471-473.
2. Byerly, M. J. & C. L. DeVane: Pharmacokinetics of clozapine and risperidone: a review of recent literature. J. Clin. Psychopharmacol. 1996, 16, 177-187.
3. Carrillo, J. A. & J. Benitez: Caffeine metabolism in a healthy Spanish population: N-acetylator phenotype and oxidation pathways. Clin. Pharmacol. Therap. 1994, 55, 293-304.
4. Centorrino, F., R. J. Baldessarini, F. R. Frankenburg, J. Kando, S. A. Volpicelli & J. G. Flood: Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Amer. J. Psychiatry 1996, 153, 820-822.
5. Eiermann, B., G. Engel, I. Johansson, U. M. Zanger & L. Bertilsson: The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Brit. J. Clin. Pharmacol. 1997, 44, 439-446.
6. Facciola, G., A. Avenoso, E. Spina & E. Perucca: Inducing effect of phenobarbital on clozapine metabolism in patients with chronic schizophrenia. Ther. Drug Monit. 1998, 20, 628-630.
7. Fang, J., R. T. Coutts, K. F. McKenna & G. B. Baker: Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine. Naunyn-Schmiedebergs. Arch. Pharmacol. 1998, 358, 592-599.
8. Freeman, D. J. & L. K. Oyewumi: Will routine therapeutic drug monitoring have a place in clozapine therapy? Clin. Pharmacokin. 1997, 32, 93-100.
9. Goff, D. C., D. C. Henderson & E. Amico: Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Amer. J. Psychiatry 1992, 149, 1189-1194.
10. Haring, C., C. Humpel, B. Auer, A. Saria, C. Barnas, W. Fleischhacker & H. Hinterhuber: Clozapine plasma levels determined by high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. 1988, 428, 160-166.
11. Haring, C., U. Meise, C. Humpel, A. Saria, W. W. Fleischhacker & H. Hinterhuber: Dose-related plasma levels of clozapine: influence of smoking behaviour, sex and age. Psychopharmacology 1989, 99, S38-S40.
12. Harris, R. Z., L. Z. Benet & J. B. Schwartz: Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995, 50, 222-239.
13. Hasegawa, M., R. Gutierrez-Esteinou, L. Way & H. Y. Meltzer: Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. J. Clin. Psychopharmacol. 1993, 13, 383-389.
14. Jann, M. W., S. R. Grimsley, E. C. Gray & W. H. Chang: Pharmacokinetics and pharmacodynamics of clozapine. Clin. Pharmacokin. 1993, 24, 161-176.
15. Jennings, T. S., A. N. Nafziger, L. Davidson & J. S. Bertino Jr: Gender differences in hepatic induction and inhibition of theophylline pharmacokinetics and metabolism. J. Lab. Clin. Med. 1993, 122, 208-216.
16. Lovdahl, M. J., P. J. Perry & D. D. Miller: The assay of clozapine and N-desmethylclozapine in human plasma by high-performance liquid chromatography. Ther. Drug Monit. 1991, 13, 69-72.
17. McCarthy, R. H.: Seizures following smoking cessation in a clozapine responder. Pharmacopsychiatry 1994, 27, 210-211.
18. Raaska, K. & P. J. Neuvonen: Serum concentrations of clozapine and N-desmethylclozapine are unaffected by the potent CYP3A4 inhibitor itraconazole. Eur. J. Clin. Pharmacol. 1998, 54, 167-170.
19. Raitasuo, V., R. Lehtovaara & M. O. Huttunen: Carbamazepine and plasma levels of clozapine. Amer. J. Psychiatry 1993, 150, 169.
20. Spina, E., A. Avenoso, G. Facciola, M. Fabrazzo, P. Monteleone, M. Maj, E. Perucca & A. P. Caputi: Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia. Int. Clin. Psychopharmacol. 1998, 13, 141-145.
21. Wetzel, H., I. Anghelescu, A. Szegedi, J. Wiesner, H. Weigmann, S. Harter & C. Hiemke: Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. J. Clin. Psychopharmacol. 1998, 18, 2-9.
22. Ziedonis, D. M., T. R. Kosten, W. M. Glazer & R. J. Frances: Nicotine dependence and schizophrenia. Hosp. Comm. Psychiatry 1994, 45, 204-206.